Journal Article

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment

G. S. Falchook, F. Vega, N. H. Dang, F. Samaniego, M. A. Rodriguez, R. E. Champlin, C. Hosing, S. Verstovsek and B. Pro

in Annals of Oncology

Published on behalf of European Society for Medical Oncology

Volume 20, issue 6, pages 1080-1085
Published in print June 2009 | ISSN: 0923-7534
Published online February 2009 | e-ISSN: 1569-8041 | DOI: http://dx.doi.org/10.1093/annonc/mdn751
Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment

Show Summary Details

Preview

Background: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined.

Methods: We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed.

Results: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain.

Conclusion: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.

Keywords: clinicopathological features; hematopoietic stem-cell transplantation; hepatosplenic T-cell lymphoma; treatment

Journal Article.  2321 words.  Illustrated.

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.